Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)

Lisa May Ling Tachiki; Daniel S. Hippe; Karly Williams Silva; Evan Thomas Hall; William McCamy; Dane Fritzsche; Andrea Perdue; Julia Majovski; Thomas Pulliam; Daniel A. Goldstein; Joshua Veatch; Joel Ho; Paul T. Nghiem; John A. Thompson; Shailender Bhatia

doi:10.1007/s00262-023-03575-4

Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)

Lisa May Ling Tachiki^*, Daniel S. Hippe, Karly Williams Silva, Evan Thomas Hall, William McCamy, Dane Fritzsche, Andrea Perdue, Julia Majovski, Thomas Pulliam, Daniel A. Goldstein, Joshua Veatch, Joel Ho, Paul T. Nghiem, John A. Thompson, Shailender Bhatia^*

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate

Abstract

The original version of this article unfortunately contained a mistake. The corrected detail is provided below: In discussion section, 6th sentence of the 10th paragraph which previously read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD. Should read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

Original language	English
Pages (from-to)	4471
Number of pages	1
Journal	Cancer Immunology, Immunotherapy
Volume	72
Issue number	12
DOIs	https://doi.org/10.1007/s00262-023-03575-4
State	Published - Dec 2023
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00262-023-03575-4

Fingerprint

Dive into the research topics of 'Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)'. Together they form a unique fingerprint.

Cite this

Tachiki, L. M. L., Hippe, D. S., Silva, K. W., Hall, E. T., McCamy, W., Fritzsche, D., Perdue, A., Majovski, J., Pulliam, T., Goldstein, D. A., Veatch, J., Ho, J., Nghiem, P. T., Thompson, J. A., & Bhatia, S. (2023). Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8). Cancer Immunology, Immunotherapy, 72(12), 4471. https://doi.org/10.1007/s00262-023-03575-4

Tachiki, Lisa May Ling ; Hippe, Daniel S. ; Silva, Karly Williams et al. / Correction to : Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8). In: Cancer Immunology, Immunotherapy. 2023 ; Vol. 72, No. 12. pp. 4471.

@article{f2277015241a4838a26a55ba81ceb174,

title = "Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)",

abstract = "The original version of this article unfortunately contained a mistake. The corrected detail is provided below: In discussion section, 6th sentence of the 10th paragraph which previously read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD. Should read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.",

author = "Tachiki, {Lisa May Ling} and Hippe, {Daniel S.} and Silva, {Karly Williams} and Hall, {Evan Thomas} and William McCamy and Dane Fritzsche and Andrea Perdue and Julia Majovski and Thomas Pulliam and Goldstein, {Daniel A.} and Joshua Veatch and Joel Ho and Nghiem, {Paul T.} and Thompson, {John A.} and Shailender Bhatia",

note = "Publisher Copyright: {\textcopyright} 2023, The Author(s).",

year = "2023",

month = dec,

doi = "10.1007/s00262-023-03575-4",

language = "אנגלית",

volume = "72",

pages = "4471",

journal = "Cancer Immunology, Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "12",

}

Tachiki, LML, Hippe, DS, Silva, KW, Hall, ET, McCamy, W, Fritzsche, D, Perdue, A, Majovski, J, Pulliam, T, Goldstein, DA, Veatch, J, Ho, J, Nghiem, PT, Thompson, JA & Bhatia, S 2023, 'Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)', Cancer Immunology, Immunotherapy, vol. 72, no. 12, pp. 4471. https://doi.org/10.1007/s00262-023-03575-4

Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8). / Tachiki, Lisa May Ling; Hippe, Daniel S.; Silva, Karly Williams et al.
In: Cancer Immunology, Immunotherapy, Vol. 72, No. 12, 12.2023, p. 4471.

Research output: Contribution to journal › Comment/debate

TY - JOUR

T1 - Correction to

T2 - Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)

AU - Tachiki, Lisa May Ling

AU - Hippe, Daniel S.

AU - Silva, Karly Williams

AU - Hall, Evan Thomas

AU - McCamy, William

AU - Fritzsche, Dane

AU - Perdue, Andrea

AU - Majovski, Julia

AU - Pulliam, Thomas

AU - Goldstein, Daniel A.

AU - Veatch, Joshua

AU - Ho, Joel

AU - Nghiem, Paul T.

AU - Thompson, John A.

AU - Bhatia, Shailender

PY - 2023/12

Y1 - 2023/12

N2 - The original version of this article unfortunately contained a mistake. The corrected detail is provided below: In discussion section, 6th sentence of the 10th paragraph which previously read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD. Should read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

AB - The original version of this article unfortunately contained a mistake. The corrected detail is provided below: In discussion section, 6th sentence of the 10th paragraph which previously read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit extended duration of treatment with RFD. Should read: In future trials, tests such as clinical biopsy or ctDNA could be used to identify patients with residual disease that may benefit from extended duration of treatment with RFD.

UR - http://www.scopus.com/inward/record.url?scp=85176800010&partnerID=8YFLogxK

U2 - 10.1007/s00262-023-03575-4

DO - 10.1007/s00262-023-03575-4

M3 - ???researchoutput.researchoutputtypes.contributiontojournal.comment???

C2 - 37979010

AN - SCOPUS:85176800010

SN - 0340-7004

VL - 72

SP - 4471

JO - Cancer Immunology, Immunotherapy

JF - Cancer Immunology, Immunotherapy

IS - 12

ER -

Tachiki LML, Hippe DS, Silva KW, Hall ET, McCamy W, Fritzsche D et al. Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8). Cancer Immunology, Immunotherapy. 2023 Dec;72(12):4471. doi: 10.1007/s00262-023-03575-4

Correction to: Extended duration of treatment using reduced‑frequency dosing of anti‑PD‑1 therapy in patients with advanced melanoma and Merkel cell carcinoma (Cancer Immunology, Immunotherapy, (2023), 72, 11, (3839-3850), 10.1007/s00262-023-03539-8)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this